RSAD2 and cancer: Transcriptional analyses of IL-6, RSAD2, IFIT1 and IFNB1 following treatment with the CPT analogue topotecan (Top) suggested that 15 and 21 out of 42 human cancer cell lines expressing STING showed increased IL-6 expression >2 fold after 6 and 24 h Top treatment, respectively (Figure 2A and Supplementary Table S1).